2. Search Result
Search Result
Results for "

LS174T

" in MedChemExpress (MCE) Product Catalog:

12

Inhibitors & Agonists

1

Peptides

1

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-153090
    Transketolase-IN-4

    		Bacterial Infection Cancer
    Transketolase-IN-4 is a potent transketolase inhibitor (IC50=3.9 μM). Transketolase-IN-4 inhibits tumor cell proliferation of SW620, LS174T, and MIA PaCa-2. Transketolase-IN-4 is a possible Mycobacterium tuberculosis DXS inhibitor, with an IC50 value of 114.1 μM .
    Transketolase-IN-4
  • HY-14392
    5,6-Dichlorobenzimidazole riboside
    3 Publications Verification

    DRB

    		 CDK Apoptosis Cancer
    5,6-Dichlorobenzimidazole riboside (DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain kinases, including casein kinase II and cell cycle-dependent kinases (CDK). 5, 6-dichlorobenzimidazole riboside has antitumor activity. 5, 6-dichlorobenzimidazole riboside can induce apoptosis .
    5,6-Dichlorobenzimidazole riboside
  • HY-P99681
    Labetuzumab govitecan

    IMMU 130; hMN-14-SN-38

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Labetuzumab govitecan (IMMU 130) is an Anti-CEACAM5/SN-38 antibody-drug conjugate (ADC). Labetuzumab govitecan consists of the antibody Labetuzumab, SN-38, and a pH-sensitive Linker. Labetuzumab govitecan can be used for research of cancers, such as colorectal cancer .
    Labetuzumab govitecan
  • HY-107425
    MZ 1
    15+ Cited Publications

    		 PROTACs Epigenetic Reader Domain Cancer
    MZ 1 is a PROTAC connected by ligands for von Hippel-Lindau and BRD4. MZ 1 potently and rapidly induces reversible, long-lasting, and selective removal of BRD4 over BRD2 and BRD3. Kds of 382/120, 119/115, and 307/228 nM for BRD4 BD1/2, BRD3 BD1/2, and BRD2 BD1/2, respectively .
    MZ 1
  • HY-P2965
    L-Lysine α-oxidase

    		Endogenous Metabolite Cancer
    L-Lysine α-oxidase is a potent anticancer agent. L-Lysine α-oxidase also a L-amino acid oxidase, deaminates L-lysine with the yield of H2O2, ammonia, and α-keto-ε-aminocaproate. L-Lysine α-oxidase shows cytotoxicity and anticancer activity .
    L-Lysine α-oxidase
  • HY-117361
    LY207702

    		Nucleoside Antimetabolite/Analog Cancer
    LY207702 is a difluorinated purine nucleoside with antitumor activity and cardiotoxicity. LY207702 is cytotoxic to CEA-positive LS174T cells (IC50=0.302 μg/mL). LY207702 can be used in the study of colon cancer .
    LY207702
  • HY-137632
    Sp-8-Cl-cAMPS

    		PKA Cancer
    Sp-8-Cl-cAMPS is an analog of cAMP (HY-B1511) and a derivative of Sp-8-Cl-cAMP. Sp-8-Cl-cAMPS inhibits the growth of human leukemia cell HL-60 and colon cancer cell LS-174T, with IC50 of 8-100 μM. Sp-8-Cl-cAMPS activates the protein kinases cAKI and cAKII, with Ka of 0.25 and 3.2 μM .
    Sp-8-Cl-cAMPS
  • HY-P10760
    PhAc-ALGP-Dox

    		Peptide-Drug Conjugates (PDCs) Cancer
    PhAc-ALGP-Dox, a peptide-drug conjugate, is a novel anticancer prodrug, with IC50 values ranged from 311 nM to 34.25 μM for TNBC (E0771), normal murine epithelium (HC-11), human TNBC (MDA-MB-231 and MDA-MB-468), human CrC (LS 174T), normal human epithelium (HME-1) cells .
    PhAc-ALGP-Dox
  • HY-171186
    EAPB0202

    		Drug Derivative Cancer
    EAPB0202 is an imidazolium and quinoxaline derivative. EAPB0202 shows significant cytotoxicity to A375 human melanoma cell line with an IC50 of 2.35 μM. EAPB0202 can be used in the study of cancer .
    EAPB0202
  • HY-151433
    Antiparasitic agent-10

    		Parasite Infection
    Antiparasitic agent-10 (Compound 94) is an anti-parasitic agent, shows anti-schistosomal activity. Antiparasitic agent-10 shows activity against adults of Schistosoma mansoni, and can be used in Schistosomiasis research .
    Antiparasitic agent-10
  • HY-111207
    CA224

    		CDK Apoptosis Cancer
    CA224 (Compound 1) is a selective and orally active Cdk4–cyclin D1 inhibitor with an IC50 of 6.2 µM. CA224 induces cell apoptosis and shows antitumor activity .
    CA224
  • HY-162704
    JMV7048

    		PROTACs Cancer
    JMV7048 is an effective PROTAC degrader targeting PXR (Pregnane X Receptor) with a DC50 of 379 nM. JMV7048 induces the polyubiquitination and degradation of PXR protein by recruiting E3 CRBN ubiquitin ligase and the 26S proteasome. JMV7048 significantly enhances the sensitivity of colon cancer stem cells to chemotherapy by reducing the expression of PXR protein in these cells, thereby significantly delaying cancer recurrence in vivo. JMV7048 is composed of the PXR agonist JMV6944 (HY-162738), linker (HY-162736), and Thalidomide 5-fluoride (HY-W087383) (Red: JMV6944; Blue: Thalidomide 5-fluoride ligand; Black: linker) .
    JMV7048

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: